Pliant Therapeutics, Inc. (NASDAQ:PLRX) Insider Hans Hull Sells 15,936 Shares

Pliant Therapeutics, Inc. (NASDAQ:PLRX) insider Hans Hull sold 15,936 shares of the stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $178,483.20. Following the completion of the transaction, the insider now directly owns 211,558 shares in the company, valued at $2,369,449.60. This trade represents a 7.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Pliant Therapeutics Stock Up 2.0 %

Shares of NASDAQ:PLRX opened at $11.14 on Friday. The stock has a market cap of $677.87 million, a P/E ratio of -3.34 and a beta of 1.05. The firm has a fifty day moving average price of $13.18 and a 200 day moving average price of $13.06. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.26 and a quick ratio of 10.26. Pliant Therapeutics, Inc. has a 1-year low of $10.22 and a 1-year high of $18.92.

Pliant Therapeutics (NASDAQ:PLRX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.04. Sell-side analysts predict that Pliant Therapeutics, Inc. will post -3.65 EPS for the current year.

Institutional Trading of Pliant Therapeutics

Large investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its stake in Pliant Therapeutics by 233.8% during the 2nd quarter. Renaissance Technologies LLC now owns 253,369 shares of the company’s stock worth $2,724,000 after purchasing an additional 177,469 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Pliant Therapeutics by 1.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 83,483 shares of the company’s stock worth $897,000 after purchasing an additional 1,191 shares during the period. Harbor Capital Advisors Inc. lifted its stake in shares of Pliant Therapeutics by 233.8% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 91,979 shares of the company’s stock worth $1,031,000 after acquiring an additional 64,422 shares during the period. Atria Investments Inc acquired a new stake in shares of Pliant Therapeutics in the 3rd quarter worth $112,000. Finally, State Street Corp lifted its stake in shares of Pliant Therapeutics by 1.9% in the 3rd quarter. State Street Corp now owns 1,402,730 shares of the company’s stock worth $15,725,000 after acquiring an additional 26,610 shares during the period. Institutional investors and hedge funds own 97.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of Pliant Therapeutics in a research report on Friday, November 8th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $40.50.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.